Cue Biopharma to Present at the 20th Annual PEGS Boston Summit
Cue Biopharma to Present at the 20th Annual PEGS Boston Summit
BOSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that it will deliver two poster presentations at the 20th PEGS Boston Summit, the Essential Protein and Antibody Engineering Summit, being held May 13-17, 2024 in Boston, MA and virtually.
波士頓，2024年5月8日（GLOBE NEWSWIRE）——Cue Biopharma, Inc.（納斯達克股票代碼：CUE）是一家處於臨床階段的生物製藥公司，正在開發一種用於選擇性調節疾病特異性T細胞的新型治療生物製劑。該公司今天宣佈，它將在2024年5月13日至17日在波士頓舉行的第20屆PEGS波士頓峯會，即必需蛋白和抗體工程峯會上發表兩份海報演講，MA 和虛擬。
Presentation Details
演示詳情
Date and Time: Monday, May 13 from 7:00 a.m. – 4:30 p.m. and Tuesday, May 14 from 9:00 a.m. – 12:00 p.m. EDT
Session: Poster Session A
Poster number: A028
Title: Immuno-STATs for Targeted Depletion of B Cells in Autoimmune Diseases
Presenter: Nitin Kumar, Scientist, Biologics Discovery and Innovation, Cue Biopharma
日期和時間：美國東部時間5月13日星期一上午7點至下午4點30分以及5月14日星期二上午9點至中午12點
會議：海報會議 A
海報編號：A028
標題：用於自身免疫性疾病中 B 細胞靶向消耗的免疫統計數據
主持人：Nitin Kumar，Cue Biopharma 生物製劑發現與創新科學家
Dr. Kumar will discuss Cue Biopharma's newly deployed CUE-500 series of bispecific Immuno-STAT biologics, designed to redirect and activate cytotoxic anti-viral memory T cells to deplete pathogenic B cells, which is a therapeutically relevant mechanism for the treatment of several autoimmune diseases.
庫馬爾博士將討論Cue Biopharma新部署的 CUE-500 系列雙特異性Immuno-Stat生物製劑，該生物製劑旨在重定向和激活細胞毒性抗病毒記憶T細胞，消耗致病性B細胞，這是一種與治療相關的機制，用於治療多種自身免疫性疾病。
Date and Time: Tuesday, May 14 from 2:00 p.m. – 4:00 p.m. and Wednesday, May 15 from 9:00 a.m. – 7:30 p.m. EDT
Session: Poster Session B
Poster number: B023
Title: Immuno-STATs (ISTs): A Novel and Unique T-Cell Engager Platform for the Treatment of Immuno-Oncology and Autoimmune Diseases
Presenter: Ahmet Vakkasoglu, Associate Director, Biologics Discovery and Innovation, Cue Biopharma
日期和時間：美國東部時間5月14日星期二下午2點至下午4點以及5月15日星期三上午9點至晚上7點30分
會議：海報會議 B
海報編號：B023
標題：Immuno-Stats（iST）：用於治療免疫腫瘤學和自身免疫性疾病的新穎而獨特的T細胞參與者平台
主持人：艾哈邁德·瓦卡索格魯，Cue Biopharma生物製劑發現與創新副總監
Dr. Vakkasoglu will present an overview of Cue Biopharma's Immuno-STAT platform and biologics. This will include a discussion of our lead oncology assets, which have demonstrated clinical anti-tumor activity, as well as an overview of our next generation platforms and molecules for the treatment of cancer, autoimmune and inflammatory diseases.
Vakkasoglu博士將概述Cue Biopharma的免疫統計平台和生物製劑。這將包括討論我們的主要腫瘤學資產，這些資產已顯示出臨床抗腫瘤活性，以及概述我們用於治療癌症、自身免疫和炎症性疾病的下一代平台和分子。
About Cue Biopharma
Cue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient's body. The company's proprietary platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body's intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation.
Cue Biopharma
臨床階段的生物製藥公司Cue Biopharma正在開發一類新型的可注射生物製劑，用於直接在患者體內選擇性地參與和調節疾病特異性T細胞。該公司的專有平台Immuno-Stat （選擇性靶向和改變 T 細胞） 生物製劑旨在通過選擇性調節疾病特異性T細胞來利用人體內在免疫系統的治療潛力，而不會受到廣泛的全身免疫調節的不利影響。
Headquartered in Boston, Massachusetts, we are led by an experienced management team and independent Board of Directors with deep expertise in immunology and immuno-oncology as well as the design and clinical development of protein biologics.
我們總部位於馬薩諸塞州波士頓，由經驗豐富的管理團隊和獨立董事會領導，他們在免疫學和免疫腫瘤學以及蛋白生物製劑的設計和臨床開發方面擁有深厚的專業知識。
For more information please visit and follow us on X and LinkedIn.
欲了解更多信息，請訪問並在 X 和 LinkedIn 上關注我們。
Investor Contact
Marie Campinell
Senior Director, Corporate Communications
Cue Biopharma, Inc.
mcampinell@cuebio.com
投資者聯繫人
瑪麗·坎皮內爾
企業傳播高級董事
Cue Biopharma, Inc.
mcampinell@cuebio.com
Media Contact
Jonathan Pappas
LifeSci Communications
jpappas@lifescicomms.com
媒體聯繫人
喬納森·帕帕斯
LifeSci
jpappas@lifescicomms.com
譯文內容由第三人軟體翻譯。